{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T18:50:45Z","timestamp":1779216645967,"version":"3.51.4"},"reference-count":29,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,15]],"date-time":"2024-07-15T00:00:00Z","timestamp":1721001600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","clinical-lung-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lung Cancer"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.cllc.2024.06.009","type":"journal-article","created":{"date-parts":[[2024,7,3]],"date-time":"2024-07-03T00:42:58Z","timestamp":1719967378000},"page":"e369-e378.e3","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Impact of Durvalumab on the Duration and Complexity of Corticosteroid Therapy for Pneumonitis After Chemoradiotherapy"],"prefix":"10.1016","volume":"25","author":[{"given":"Saori","family":"Murata","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9090-801X","authenticated-orcid":false,"given":"Hidehito","family":"Horinouchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Momoko","family":"Morishita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sawako","family":"Kaku","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuki","family":"Shinno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yusuke","family":"Okuma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsuya","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasushi","family":"Goto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noboru","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tairo","family":"Kashihara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kae","family":"Okuma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiko","family":"Kusumoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuichiro","family":"Ohe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"Suppl 1","key":"10.1016\/j.cllc.2024.06.009_bib0001","doi-asserted-by":"crossref","first-page":"S108","DOI":"10.1038\/bjc.2015.49","article-title":"Stage at diagnosis and early mortality from cancer in England","volume":"112","author":"McPhail","year":"2015","journal-title":"Br J Cancer"},{"issue":"1","key":"10.1016\/j.cllc.2024.06.009_bib0002","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1097\/JTO.0b013e3181c5920c","article-title":"Trends in stage distribution for patients with non-small cell lung cancer: a national cancer database survey","volume":"5","author":"Morgensztern","year":"2010","journal-title":"J Thorac Oncol"},{"issue":"5","key":"10.1016\/j.cllc.2024.06.009_bib0003","doi-asserted-by":"crossref","first-page":"409","DOI":"10.3322\/caac.21731","article-title":"Cancer treatment and survivorship statistics, 2022","volume":"72","author":"Miller","year":"2022","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.cllc.2024.06.009_bib0004","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.lungcan.2021.12.005","article-title":"Deciphering the clinical features of heterogeneous stage III non-small cell lung cancer in Japanese real-world clinical practice: Expanded cohort of the SOLUTION study","volume":"165","author":"Murakami","year":"2021","journal-title":"Lung Cancer"},{"issue":"7","key":"10.1016\/j.cllc.2024.06.009_bib0005","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1200\/JCO.19.01162","article-title":"Long-term results of NRG oncology RTOG 0617: standard- versus high-dose chemoradiotherapy with or without cetuximab for unresectable stage III non-small-cell lung cancer","volume":"38","author":"Bradley","year":"2020","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.cllc.2024.06.009_bib0006","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1200\/JCO.21.01308","article-title":"Five-year survival outcomes from the PACIFIC trial: durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer","volume":"40","author":"Spigel","year":"2022","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.cllc.2024.06.009_bib0007","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/S1470-2045(17)30380-7","article-title":"Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial","volume":"18","author":"Shaverdian","year":"2017","journal-title":"Lancet Oncol"},{"issue":"9","key":"10.1016\/j.cllc.2024.06.009_bib0008","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1001\/jamaoncol.2019.1478","article-title":"Effect of pembrolizumab after stereotactic body radiotherapy vs pembrolizumab alone on tumor response in patients with advanced non-small cell lung cancer: results of the PEMBRO-RT phase 2 randomized clinical trial","volume":"5","author":"Theelen","year":"2019","journal-title":"JAMA Oncol"},{"issue":"20","key":"10.1016\/j.cllc.2024.06.009_bib0009","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","article-title":"Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer","volume":"377","author":"Antonia","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cllc.2024.06.009_bib0010","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.lungcan.2021.08.019","article-title":"Real-world survey of pneumonitis and its impact on durvalumab consolidation therapy in patients with non-small cell lung cancer who received chemoradiotherapy after durvalumab approval (HOPE-005\/CRIMSON)","volume":"161","author":"Saito","year":"2021","journal-title":"Lung Cancer"},{"issue":"11","key":"10.1016\/j.cllc.2024.06.009_bib0011","doi-asserted-by":"crossref","first-page":"6690","DOI":"10.21037\/jtd-20-1792","article-title":"Implications of pneumonitis after chemoradiation and durvalumab for locally advanced non-small cell lung cancer","volume":"12","author":"Hassanzadeh","year":"2020","journal-title":"J Thorac Dis"},{"issue":"1","key":"10.1016\/j.cllc.2024.06.009_bib0012","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.cllc.2021.08.006","article-title":"Real-World incidence of pneumonitis in patients receiving durvalumab","volume":"23","author":"LeClair","year":"2022","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.cllc.2024.06.009_bib0013","series-title":"AJCC Cancer Staging Manual","year":"2017"},{"key":"10.1016\/j.cllc.2024.06.009_sbref0014","series-title":"Common Terminology Criteria for Adverse Events (CTCAE)","year":"2010"},{"issue":"3","key":"10.1016\/j.cllc.2024.06.009_bib0015","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/bmt.2012.244","article-title":"Investigation of the freely available easy-to-use software 'EZR' for medical statistics","volume":"48","author":"Kanda","year":"2013","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"10.1016\/j.cllc.2024.06.009_bib0016","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1200\/JCO.2016.69.1378","article-title":"Impact of intensity-modulated radiation therapy technique for locally advanced non-small-cell lung cancer: a secondary analysis of the NRG oncology RTOG 0617 randomized clinical trial","volume":"35","author":"Chun","year":"2017","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.cllc.2024.06.009_bib0017","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s12890-020-01376-4","article-title":"Radiation-induced lung injury: current evidence","volume":"21","author":"Arroyo-Hern\u00e1ndez","year":"2021","journal-title":"BMC Pulm Med"},{"issue":"36","key":"10.1016\/j.cllc.2024.06.009_bib0018","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.1200\/JCO.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update","volume":"39","author":"Schneider","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cllc.2024.06.009_bib0019","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.ejca.2020.10.008","article-title":"Durvalumab therapy following chemoradiation compared with a historical cohort treated with chemoradiation alone in patients with stage III non-small cell lung cancer: a real-world multicentre study","volume":"142","author":"Desilets","year":"2021","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.cllc.2024.06.009_bib0020","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.lungcan.2020.05.035","article-title":"Real world data of durvalumab consolidation after chemoradiotherapy in stage III non-small-cell lung cancer","volume":"146","author":"Jung","year":"2020","journal-title":"Lung Cancer"},{"issue":"1","key":"10.1016\/j.cllc.2024.06.009_bib0021","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1186\/s13014-020-01654-9","article-title":"Radiation-induced lung toxicity - cellular and molecular mechanisms of pathogenesis, management, and literature review","volume":"15","author":"K\u00e4smann","year":"2020","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.cllc.2024.06.009_bib0022","doi-asserted-by":"crossref","unstructured":"Yin J, Wu Y, Yang X, et al. Checkpoint inhibitor pneumonitis induced by Anti-PD-1\/PD-L1 therapy in non-small-cell lung cancer: occurrence and mechanism. Front Immunol. 2022 ;13:830631. doi: 10.3389\/fimmu.2022.830631.","DOI":"10.3389\/fimmu.2022.830631"},{"issue":"7","key":"10.1016\/j.cllc.2024.06.009_bib0023","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1200\/JCO.2016.68.2005","article-title":"Pneumonitis in patients treated with anti-programmed death-1\/programmed death ligand 1 therapy","volume":"35","author":"Naidoo","year":"2017","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.cllc.2024.06.009_bib0024","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000840","article-title":"Chronic immune checkpoint inhibitor pneumonitis","volume":"8","author":"Naidoo","year":"2020","journal-title":"J Immunother Cancer"},{"issue":"3","key":"10.1016\/j.cllc.2024.06.009_bib0025","doi-asserted-by":"crossref","first-page":"e264","DOI":"10.1016\/j.cllc.2021.07.005","volume":"23","author":"De Ruysscher","year":"2022","journal-title":"Clin Lung Cancer"},{"issue":"6","key":"10.1016\/j.cllc.2024.06.009_bib0026","doi-asserted-by":"crossref","first-page":"e342","DOI":"10.1016\/j.cllc.2022.04.003","article-title":"Rationale and design of the phase III KEYLYNK-012 study of pembrolizumab and concurrent chemoradiotherapy followed by pembrolizumab with or without olaparib for stage iii non-small-cell lung cancer","volume":"23","author":"Jabbour","year":"2022","journal-title":"Clin Lung Cancer"},{"issue":"6","key":"10.1016\/j.cllc.2024.06.009_bib0027","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/S1470-2045(22)00226-1","article-title":"Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study","volume":"23","author":"Cho","year":"2022","journal-title":"Lancet Oncol"},{"issue":"29","key":"10.1016\/j.cllc.2024.06.009_bib0028","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1200\/JCO.22.00227","article-title":"COAST: an open-label, phase II, multidrug platform study of durvalumab alone or in combination with oleclumab or monalizumab in patients with unresectable, stage III non-small-cell lung cancer","volume":"40","author":"Herbst","year":"2022","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.cllc.2024.06.009_bib0029","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.ygyno.2021.05.012","article-title":"Risk of pneumonitis in cancer patients treated with PARP inhibitors: a meta-analysis of randomized controlled trials and a pharmacovigilance study of the FAERS database","volume":"162","author":"Ma","year":"2021","journal-title":"Gynecol Oncol"}],"container-title":["Clinical Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730424001360?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730424001360?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,25]],"date-time":"2024-10-25T15:48:40Z","timestamp":1729871320000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525730424001360"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":29,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["S1525730424001360"],"URL":"https:\/\/doi.org\/10.1016\/j.cllc.2024.06.009","relation":{},"ISSN":["1525-7304"],"issn-type":[{"value":"1525-7304","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of Durvalumab on the Duration and Complexity of Corticosteroid Therapy for Pneumonitis After Chemoradiotherapy","name":"articletitle","label":"Article Title"},{"value":"Clinical Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cllc.2024.06.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}